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MKP-1 reduces Aβ generation and alleviates cognitive
impairments in Alzheimer’s disease models
Yehong Du1, Yexiang Du2, Yun Zhang3, Zhilin Huang1, Min Fu1, Junjie Li1, Yayan Pang1, Peng Lei4, Yu Tian Wang1,5, Weihong Song1,3,
Guiqiong He2 and Zhifang Dong1
Mitogen-activated protein kinase (MAPK) phosphatase 1 (MKP-1) is an essential negative regulator of MAPKs by dephosphorylating
MAPKs at both tyrosine and threonine residues. Dysregulation of the MAPK signaling pathway has been associated with Alzheimer’s
disease (AD). However, the role of MKP-1 in AD pathogenesis remains elusive. Here, we report that MKP-1 levels were decreased in
the brain tissues of patients with AD and an AD mouse model. The reduction in MKP-1 gene expression appeared to be a result of
transcriptional inhibition via transcription factor specificity protein 1 (Sp1) cis-acting binding elements in the MKP-1 gene promoter.
Amyloid-β (Aβ)-induced Sp1 activation decreased MKP-1 expression. However, upregulation of MKP-1 inhibited the expression of
both Aβ precursor protein (APP) and β-site APP-cleaving enzyme 1 by inactivating the extracellular signal-regulated kinase 1/2
(ERK)/MAPK signaling pathway. Furthermore, upregulation of MKP-1 reduced Aβ production and plaque formation and improved
hippocampal long-term potentiation (LTP) and cognitive deficits in APP/PS1 transgenic mice. Our results demonstrate that MKP-1
impairment facilitates the pathogenesis of AD, whereas upregulation of MKP-1 plays a neuroprotective role to reduce Alzheimer-
related phenotypes. Thus, this study suggests that MKP-1 is a novel molecule for AD treatment.
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INTRODUCTION
Alzheimer’s disease (AD) is an age-related neurodegenerative
disease that leads to dementia and is characterized by extracellular
senile plaques, intracellular neurofibrillary tangles and synaptic
abnormalities. Amyloid-β (Aβ) peptides, the main component of
senile plaques, are generated from Aβ precursor protein (APP) by
sequential proteolytic cleavages by β- and γ-secretases.1 β-Site
APP-cleaving enzyme 1 (BACE1) cleaves APP at the Asp1 or Glu2
site to generate a membrane-bound C-terminal fragment (CTF) of
99 amino acids (C99) or 89 amino acids (C89).3–5 C99 is further
cleaved by γ-secretase to produce Aβ and the APP intracellular
domain. Notably, in addition to the long-known secretases, recent
studies have discovered that APP can be cleaved at a novel
cleavage site termed η-site to produce CTF-η,6,7 which is partially
mediated by membrane-bound matrix metalloproteinases such as
MT5-MMP and is known as η-secretase activity. Then, CTF-η is
cleaved by α- and β-secretases to release the long and short Aη
peptide, including Aη-α and Aη-β, respectively.6,8 Previous studies
have revealed that Aβ deregulates neurotransmitter release from
the presynaptic site in both primary neurons and AD model mouse
brains.9–11 Aβ directly interacts with cell membranes and
membrane receptors to exert its neurotoxic effect and then
initiates spine density decrease, synapse loss, and synaptic
plasticity impairment,2,12,13 which may lead to neuronal perturba-
tions and memory decline during AD.
Mitogen-activated protein kinases (MAPKs), which are serine/
threonine protein kinases, play critical roles in cellular signal
transduction. In mammals, MAPKs are comprised of extracellular
signal-regulated kinase 1/2 (ERK), P38 kinases (P38), and c-Jun N-
terminal kinases (JNK).14 In AD mouse models, the JNK signaling
pathway is overactivated in the spine before cognitive decline,
and its specific inhibitor D-JNKI1 is able to suppress synaptic
shrinkage and postsynaptic protein loss.15 In the brains of AD
patients, P38 is highly expressed.16 Aβ-induced P38 activation
increases tau phosphorylation17 and promotes the amyloidogenic
processing of APP.18 In the adult nervous system, ERK activation is
required for synaptic plasticity and memory formation.19,20
However, overactivated ERK is associated with neurofibrillary
tangle formation and early AD-related protein deposition, leading
to hippocampal function impairment and memory deficits in both
AD patients and mouse models.21–24 Collectively, these studies
indicate that MAPKs could accelerate AD development. Prevention
of MAPK overactivation can reduce Aβ deposition, tau hyperpho-
sphorylation,25 neuronal apoptosis,26 and memory impairment.27
MAPKs could be potential targets for novel and effective
therapeutics of AD.
MAPK phosphatase 1 (MKP-1) inhibits MAPK activity by depho-
sphorylating MAPK at the tyrosine and threonine residues.28–30
Although MKP-1 is widely expressed in rodent brain regions,
including the hippocampus,31 cortex,32 ventral tegmental area,33
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striatum and thalamus,34 its neurological function is poorly
understood. Recent studies have shown that MKP-1 may serve
as a pivotal regulator of synaptogenesis. Dysregulation of MKP-1
might disrupt neuronal development and cognitive function.35 A
recent study has shown that MKP-1 exerts a neuroprotective role
in Aβ-induced apoptosis, neuroinflammation, and oxidative stress
by inactivating JNK.36 However, the exact role of MKP-1 in AD
pathogenesis remains largely unclear.
In this study, we determined that MKP-1 levels were reduced in
the brain tissues of patients with AD and a mouse model of AD.
This reduction was associated with Aβ-induced Sp1 activation.
Furthermore, we found that inhibition of the ERK/MAPK signaling
pathway by MKP-1-reduced APP and BACE1 expression to
generate Aβ, resulting in the inhibition of plaque formation,
improvement of hippocampal long-term potentiation (LTP) and
memory decline in APP/PS1 double transgenic mice. Our work
demonstrates the neuroprotective effect of MKP-1 for potential
AD treatment.
RESULTS
Reduced MKP-1 expression in the brains of AD patients and a
mouse model of AD
To examine whether there is an alteration of MKP-1 levels in AD,
brain samples from patients with AD and control subjects were
analyzed. The results showed that the expression of MKP-1 was
markedly decreased in the hippocampus of AD patients (n= 6,
64.98 ± 10.77%, p= 0.023; Fig. 1a) relative to controls (n= 4). In
addition to the hippocampus, other brain regions also play critical
roles in AD development. Therefore, we next tested MKP-1
expression in the temporal cortex of human tissues and found that
MKP-1 expression was also markedly decreased in AD patients (n
= 6, 55.95 ± 10.94%, p= 0.009; Fig. 1b) relative to controls (n= 4).
Next, we examined MKP-1 expression in the APP/PS1 double
transgenic mouse model of AD. Consistent with previous
reports,31–34 MKP-1 was widely distributed throughout the brain
tissues of APP/PS1 transgenic mice (Supplementary Fig. S1).
Similar to the findings in AD patients, MKP-1 expression was
significantly reduced in the hippocampus of AD mice at 9 months
old (28.46 ± 5.63%, p < 0.001; Fig. 1c) compared with their wild-
type littermates. In addition, the reduction in MKP-1 in AD mice
occurred in an age-dependent manner (66.79 ± 2.74% at 9 m and
32.31 ± 4.45% at 12 m relative to 3 m; Fig. 1d). We further
examined whether mutant APP affects the expression of MKP-1
in N2A cells stably expressing human Swedish mutant APP695
(N2AAPP). Swedish mutant APP was highly expressed in N2AAPP
stable cells (349.17 ± 34.39%, p < 0.001; Fig. 1e) compared with
N2A cells. Consistent with the downregulation of MKP-1 in both
AD patients and AD mice, MKP-1 expression was also significantly
decreased in N2AAPP cells (40.65 ± 5.98%, p < 0.001; Fig. 1f)
compared with non-Swedish mutant APP-expressing cells. These
data clearly showed that MKP-1 expression was decreased in AD,
as observed in AD patients, a mouse model of AD and cells
expressing the AD-associated mutant APP gene.
Transcriptional downregulation of MKP-1 gene expression by Sp1
To determine whether the MKP-1 reduction in AD is attributed to
Aβ, N2A cells were treated with different concentrations of Aβ. The
results showed that Aβ treatment markedly decreased MKP-1
protein levels in a dose-dependent manner (74.59 ± 7.72% at
2.5 µM; 55.87 ± 6.10% at 5 µM; 54.95 ± 9.1% at 10 µM; 49.21 ± 8.04%
at 20 µM; and 45.63 ± 5.10% at 50 µM; Fig. 2a). To determine
whether the Aβ-induced reduction in MKP-1 is owing to impaired
synthesis or enhanced degradation, cycloheximide (CHX) assay was
performed. CHX was added to the cells to inhibit protein synthesis,
and the MKP-1 protein level was analyzed. We found that 10 µM Aβ
treatment had no effect on MKP-1 catabolism (Fig. 2b). However,
Aβ treatment significantly decreased MKP-1 mRNA levels (Fig. 2c).
These results indicate that Aβ inhibits MKP-1 gene expression at
the transcriptional level but does not affect protein degradation.
To examine the transcriptional regulation of MKP-1 gene
expression, human MKP-1 promoter plasmids were constructed
Fig. 1 MKP-1 was decreased in AD. a, b The protein level of MKP-1 assessed by western blot in the hippocampus a and temporal cortex b of
control (Ctrl) and AD patients. *p < 0.05 by unpaired Student’s t test. n= 4–6 in each group. c The protein level of MKP-1 in the hippocampus
of wild-type (WT) and APP/PS1 transgenic AD model mice at the age of 9 months. ***p < 0.001 by unpaired Student’s t test. n= 6 in each
group. d The protein level of MKP-1 in the hippocampus of AD mice at different ages. ***p < 0.001 by one-way ANOVA. n= 3 in each group. e,
f The protein levels of APP e and MKP-1 f assessed by western blot in lysates of N2A and N2AAPP cells. ***p < 0.001 by unpaired Student’s t test.
n= 3–6 in each group.
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that contained different lengths of the MKP-1 promoter upstream
of the firefly luciferase reporter gene in the promoter-less vector
pGL4.10-basic (Supplementary Fig. S2a). HEK 293 cells were
transfected with these plasmids, and a luciferase assay was
performed to examine the promoter activity.37 MKP-1-A, contain-
ing the longest MKP-1 promoter fragments from −763 bp to
+342 bp of the transcription start site at +1, had robust promoter
activity. Deletion of 534 bp at the 5’-flanking region from −763 to
−229 resulted in significantly higher promoter activity, indicating
that there are negative regulatory cis-acting element(s) in the
−763 to −229 region. The deletion of 120 bp from +342 to +222
at the 3’-flanking region of the promoter had little effect on MKP-1
promoter activity. There was no promoter activity in the −47 to
+342 or +222 region, but there was a high promoter activity in
the region from −229 to −47, indicating that the region between
−229 and −47 contains a minimal sequence for the MKP-1
promoter (Supplementary Fig. S2b).
Using Genomatix and TFSearch software to analyze potential
regulatory cis-acting elements in the MKP-1 promoter, several
potential Sp1-binding sites were identified in the MKP-1 promoter.
To examine whether Sp1 regulates transcriptional activation of the
MKP-1 gene promoter, the MKP-1 promoter plasmid MKP-1-A and
Sp1 expression plasmid were cotransfected into HEK 293 cells.
Compared with the control vector transfection, coexpression of
Sp1 significantly decreased MKP-1 promoter activity (Fig. 2d).
Electrophoretic mobility shift assay (EMSA) was performed, and
the results showed that there were five Sp1-binding sites in the
MKP-1 promoter (Fig. 2e–i). To examine whether all or some
Fig. 2 Sp1 inhibited MKP-1 expression in N2AAPP cells. a The protein level of MKP-1 assessed by western blot in N2A cells after treatment with
different concentrations of Aβ. **p < 0.01 and ***p < 0.001 by one-way ANOVA. n= 5 in each group. b The effect of Aβ (10 µM) on the
degradation of MKP-1 assessed by half-life measurements in N2A cells treated with 100 μg/ml cycloheximide (CHX). p= 0.352 by two-way
ANOVA. n= 5–8 in each group. c The mRNA level of MKP-1 assessed by qPCR in N2A cells after treatment with different concentrations of Aβ.
*p < 0.05 and **p < 0.01 by one-way ANOVA. n= 6 in each group. d The promoter activity of MKP-1 assessed by luciferase assay in N2A cells
after treatment with different concentrations of Aβ. *p < 0.05, **p < 0.01 and ***p < 0.001 by one-way ANOVA. n= 5 in each group. e–i
Functional Sp1-binding sites to the MKP-1 gene promoter. EMSA with MKP-1 Sp1 probe in nuclear extract of HEK 293 cells transfected with
Sp1 expression plasmid. Lane 1 is the labeled human consensus Sp1 probe only. Lane 2 shows a shifted DNA–protein complex formed
between the labeled Sp1 and nuclear extracts. Competition assays were performed by further adding different competitions of
oligonucleotides that included consensus wild-type Sp1 (lane 3), mutant Sp1 (lane 4), putative Sp1-binding site 1 in MKP-1 and mutant Sp1-
binding site 1 in MKP-1 (lanes 5 and 6 in a), putative Sp1-binding site 2 in MKP-1 and mutant Sp1-binding site 2 in MKP-1 (lanes 5 and 6 in b),
putative Sp1-binding site 3 in MKP-1 and mutant Sp1-binding site 3 in MKP-1 (lanes 5 and 6 in c), putative Sp1-binding site 4 in MKP-1 and
mutant Sp1-binding site 4 in MKP-1 (lanes 5 and 6 in d), putative Sp1-binding site 5 in MKP-1 and mutant Sp1-inding site 5 in MKP-1 (lanes 5
and 6 in e). Lane 7 shows the supershifted band with the anti-Sp1 antibody. j, k Effects of different Sp1-binding sites in MKP-1 on the
promoter activity of MKP-1 as assessed by luciferase assay. *p < 0.05, **p < 0.01 and ***p < 0.001 by one-way ANOVA. n= 4 in each group. l
Effect of different concentrations of Aβ on the expression of Sp1 as assessed by western blot in HEK 293 cells. *p < 0.05 and **p < 0.01 by one-
way ANOVA. n= 4 in each group. m, n The protein level of Sp1 assessed by western blot in the hippocampus m and temporal cortex n of
control (Ctrl) and AD patients. *p < 0.05 by unpaired Student’s t test. n= 4 to 6 in each group.
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binding sites are physiologically functional in regulating transacti-
vation of the MKP-1 promoter, the sites were abolished by
mutations. Mutations in binding sites 2, 3, and 4 significantly
decreased MKP-1 promoter activity to 28.49 ± 8.60%, 64.17 ±
12.45%, and 53.28 ± 13.22%, respectively, whereas mutations in
binding sites 1 and 5 did not affect MKP-1 promoter activity
(Fig. 2j). These results demonstrate that Sp1 negatively regulates
the transcriptional activation of MKP-1 gene expression.
Sp1 mediates Aβ-induced inhibition of MKP-1 expression
To investigate whether the Aβ-induced reduction in MKP-1
expression is caused by its inhibitory effect on the transcriptional
activation of the MKP-1 gene, HEK 293 cells were transfected with
the MKP-1 gene promoter plasmid MKP-1-A and then treated with
Aβ. We found that Aβ treatment significantly reduced the
promoter activity of MKP-1 (57.40 ± 4.41% at 2.5 µM; 79.89 ±
8.58% at 5 µM; 74.32 ± 3.20% at 10 µM; 75.97 ± 6.75% at 20 µM;
and 75.63 ± 3.49% at 50 µM; Fig. 2k). As we showed that Sp1
transcriptionally inhibited MKP-1 gene expression, we next wanted
to examine whether Sp1 mediates the inhibitory effect of Aβ on
MKP-1 expression. The results showed that after treatment with
different concentrations of Aβ the Sp1 protein level was increased
in HEK 293 cells to 254.93 ± 58.08% at 10 µM, 246.35 ± 15.20% at
20 µM, and 275.11 ± 48.63% at 50 µM (Fig. 2l). Consistent with this
result, Sp1 expression was markedly increased in the hippocampus
(457.51 ± 112.89%, p= 0.025; Fig. 2m) and temporal cortex
(190.51 ± 33.85%, p= 0.033; Fig. 2n) of AD patients (n= 6) relative
to controls (n= 4). These data demonstrate that Aβ increases Sp1
expression and downregulates MKP-1 expression.
MKP-1 affects APP processing by regulating APP and BACE1
expression
Our study has shown that MKP-1 expression is decreased in the
brain tissues of AD patients and mice. To further explore whether
MKP-1 affects APP processing and Aβ generation, N2AAPP cells
were infected with lentivirus carrying the MKP-1 gene (LVMKP-1).
Overexpression of MKP-1 significantly decreased the levels of APP
to 57.69 ± 6.47% (p= 0.044, Fig. 3a, b) and the β-secretase BACE1
to 68.98 ± 12.34% (p= 0.030, Fig. 3a, e). Aβ40 and Aβ42 were also
significantly reduced to 27.81 ± 2.42 pg/ml (Fig. 3f) and 33.18 ±
5.32 pg/ml (Fig. 3g), respectively. In contrast, downregulation of
MKP-1 expression by MKP-1 shRNA (LVshMKP-1) markedly increased
the expression of APP to 171.78 ± 28.19% (p= 0.021) and its CTFs
C89 to 270.83 ± 83.08% (p= 0.023; Fig. 3a, c) and C99 to 226.48 ±
30.18% (p= 0.036; Fig. 3a, d). Aβ40 and Aβ42 increased to 54.69 ±
7.80 pg/ml (Fig. 3f) and to 109.7 ± 9.54 pg/ml (Fig. 3g), respectively.
To examine whether MKP-1 regulates APP and BACE1 gene
expression, we first measured the APP and BACE1 mRNA levels in
N2AAPP cells. We found that overexpression of MKP-1 by the MKP-1
lentivirus significantly decreased the levels of APP mRNA to 56.68 ±
10.20% (p= 0.017; Fig. 3h) and BACE1 mRNA to 37.22 ± 15.82% (p=
0.038; Fig. 3i). The promoter activities of APP and BACE1 were further
assayed by cotransfecting N2AAPP cells with the human APP
promoter- or human BACE1 promoter-containing plasmid and
MKP-1 lentivirus. Luciferase assays showed that MKP-1 overexpres-
sion significantly decreased the APP promoter activity of pAPP-Luc
(79.33 ± 18.45% relative to control, p < 0.001; Fig. 3j) and BACE1
promoter activity of pB1-A-Luc (70.95 ± 3.91% relative to control,
p= 0.004; Fig. 3k). To detect whether MKP-1 affects the degradation
of the APP and BACE1 proteins, a CHX assay was performed. We
observed that MKP-1 did not affect the degradation of APP (Fig. 3l)
or BACE1 (Fig. 3m). These results suggest that MKP-1 downregulates
APP and BACE1 expression and APP processing to generate Aβ.
MKP-1 inhibits the amyloidogenic process through the ERK/MAPK
signaling pathway
Next, we detected the influence of MKP-1 on ERK, P38 and JNK.
The results showed that P-ERK, P-P38 and P-JNK were significantly
increased in N2AAPP cells compared with N2A control cells
(Supplementary Fig. S3). To examine the role of MKP-1 in MAPK
activation, LVMKP-1 or LVshMKP-1 were transfected into N2A
APP cells
to overexpress or knockdown MKP-1, respectively. MKP-1 knock-
down led to a significant increase in P-ERK (208.82 ± 34.00%
relative to control, p < 0.001), P-JNK (223.46 ± 43.63%, p < 0.001)
and P-P38 (226.65 ± 20.28% relative to control, p < 0.001) (Fig.
4a–e). In contrast, overexpression of MKP-1 significantly decreased
P-ERK (38.71 ± 3.25% relative to control, p= 0.035) and P-P38
(56.33 ± 3.90% relative to control, p= 0.024) but not P-JNK
(105.83 ± 25.13% relative to control, p= 0.998) (Fig. 4a–e).
Furthermore, treatment with an ERK inhibitor (U0126) but not
JNK inhibitor (SP600125) or P38 inhibitor (SB203580) significantly
decreased the expression of APP, C89, C99 and BACE1 (Fig. 4f–j). In
addition, the combined application of U0126, SP600125 and
SB203580 had the same effect on APP processing as U0126
treatment alone (Fig. 4f–j), suggesting that inhibition of the ERK/
MAPK signaling pathway is sufficient to inhibit the amyloidogenic
processing of APP. Furthermore, U0126 markedly inhibited the
promoter activities of APP to 41.28 ± 2.52% (p < 0.001; Fig. 4k) and
BACE1 to 67.52 ± 10.83% (p= 0.040; Fig. 4l) and reduced the APP
mRNA levels down to 38.06 ± 12.05% relative to control (p= 0.036;
Fig. 4m) and BACE1 mRNA level down to 54.35 ± 10.45% (p=
0.032; Fig. 4n). U0126 treatment did not affect APP or BACE1
protein degradation (Fig. 4o, p). Our results clearly demonstrate
that MKP-1 inhibits APP and BACE1 gene expression and the
amyloidogenic processing of APP through the ERK/MAPK signal-
ing pathway.
MKP-1 reduces Aβ generation and plaque formation in APP/PS1
mice
To determine the role of the MKP-1-mediated ERK/MAPK signaling
pathway in AD pathogenesis and its therapeutic potential, we
generated an adeno-associated viruses carrying MKP-1 cDNA
(AAVMKP-1) and MKP-1 shRNA (AAVshMKP-1). The viruses were
microinjected into the lateral ventricle of APP/PS1 mice to
overexpress or knockdown MKP-1 in the AD mouse model (Fig.
5a, b). Consistent with the observations in N2AAPP cells, the P-ERK
level was significantly increased in AD mice (155.93 ± 24.54%, p=
0.034; Fig. 5a, c) compared with WT mice. Overexpression of MKP-
1 by AAVMKP-1 inhibited P-ERK in AD mice (p < 0.001), whereas
downregulation of MKP-1 expression by AAVshMKP-1 increased P-
ERK (p < 0.001) (Fig. 5a, c).
Neuritic plaques are a pathological hallmark of AD. Our results
have shown the effect of MKP-1 on APP processing and Aβ
generation in vitro and its underlying mechanism. To confirm the
effect in vivo, APP processing and Aβ generation were assayed in
the AD transgenic mouse model infected with AAVMKP-1 or
AAVshMKP-1. Overexpression of MKP-1 by AAVMKP-1 in the brains of
AD mice decreased the expression of APP (AAVEGFP: 221.22 ±
57.47% vs. AAVMKP-1: 117.09 ± 23.97%, p= 0.037), C89 (AAVEGFP:
169.42 ± 29.51% vs. AAVMKP-1: 106.44 ± 15.11%, p= 0.039), C99
(AAVEGFP: 195.15 ± 35.38% vs, AAVMKP-1: 121.52 ± 33.51%, p=
0.016), and BACE1 (AAVEGFP: 156.70 ± 13.56% vs. AAVMKP-1:
105.18 ± 17.36%, p= 0.005) (Fig. 5h–l). However, the expression
of APP, C89, C99 and BACE1 was not affected by MKP-1
knockdown with AAVshMKP-1 (Fig. 5h–l).
Overexpression of MKP-1 by AAVMKP-1 led to a marked
reduction in the levels of Aβ40 (WT: 21.56 ± 11.44 pg/mg; AD+
AAVEGFP: 288.67 ± 56.03 pg/mg; and AD+ AAVMKP-1: 125.30 ±
39.61 pg/mg) (p= 0.025; Fig. 5f) and Aβ42 (WT: 52.70 ± 10.40 pg/
mg; AD+ AAVEGFP: 221.15 ± 34.02 pg/mg; and AD+ AAVMKP-1:
121.03 ± 22.95 pg/mg) (p= 0.049; Fig. 5g) in the mouse brains. In
contrast, knockdown of MKP-1 by AAVshMKP-1 increased the levels
of Aβ40 (AD+ AAVshMKP-1: 539.84 ± 88.00 pg/mg) (p < 0.001; Fig. 5f)
and Aβ42 (AD+ AAVshMKP-1: 425.10 ± 53.85 pg/mg) (p= 0.003; Fig.
5g). To determine whether MKP-1 affects AD-related neuropathol-
ogies, the formation of neuritic plaques was examined in the APP/
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PS1 mice. Overexpression of MKP-1 by AAVMKP-1 significantly
decreased the number of neuritic plaques (p= 0.028; Fig. 5d, e).
However, downregulation of MKP-1 expression by AAVshMKP-1 had
no effect on plaque formation. Collectively, these data demon-
strate that overexpression of MKP-1 inhibits Aβ generation and
neuritic plaque formation in AD transgenic mice.
MKP-1 alleviates synaptic and cognitive impairments in APP/PS1
mice
Our study has indicated that overexpression of MKP-1 can
ameliorate neuropathology in AD mice. We next wanted to detect
whether MKP-1 could improve cognitive impairments. APP/PS1
mice were treated with AAVMKP-1 or AAVshMKP-1 at 3 and 6 months
of age and subjected to the Morris water maze test at 9 months of
age. Compared with WT mice, the transgenic mice treated with
control AAV displayed significantly impaired spatial learning with
longer escape latency for finding the hidden platform (p= 0.007;
Fig. 6a). However, upregulation of MKP-1 by AAVMKP-1 markedly
shortened the escape latency (p= 0.016; Fig. 6a), whereas
downregulation of MKP-1 by AAVshMKP-1 increased the escape
latency in the AD mice (p= 0.006; Fig. 6a). The probe test showed
that upregulation of MKP-1 enhanced spatial memory retrieval, as
the AAVMKP-1-treated mice had an increased number of entries
into the platform zone (p= 0.017; Fig. 6b) and spent much more
time in the target quadrant (p= 0.032; Fig. 6c). We also treated
another group of mice at a later stage by microinjecting the AD
mice with AAV at 6 and 9 months of age, and performed the
behavioral test at 12 months. Similar results were observed.
AAVMKP-1 decreased escape latency during hidden platform
training (p < 0.001; Fig. 6d). The probe test revealed that mice
treated with AAVMKP-1 had more entries into the platform zone
(p= 0.037; Fig. 6e) and spent much more time in the target
quadrant (p= 0.034; Fig. 6f). These data clearly demonstrate that
upregulation of MKP-1 expression ameliorated the cognitive
impairments in the AD transgenic mouse model.
Hippocampal LTP is considered to be the cellular mechanism
underlying learning and memory. Next, we further investigated
the influence of MKP-1 on hippocampal LTP in the CA1 area of AD
mice at 12 months of age. We found that LTP was clearly impaired
in APP/PS1 mice (127.79 ± 1.23% vs. 172.06 ± 2.24% in control to
baseline, p < 0.001; Fig. 6g–i). Upregulation of MKP-1 by AAVMKP-1
reversed the impairment of LTP (194.68 ± 9.32% to baseline, p <
Fig. 3 MKP-1 reduced APP processing in N2AAPP cells. a–e The protein levels of APP b, C89 c, C99 d, and BACE1 e, assessed by western blot in
lysates of N2AAPP cells after overexpression of MKP-1 by LVMKP-1 or knockdown of MKP-1 by LVshMKP-1. *p < 0.05 by one-way ANOVA. n= 5–6 in
each group. f, g The generation of Aβ40 f and Aβ42 g as measured by ELISA in the conditioned media of N2AAPP cells after overexpression of
MKP-1 by LVMKP-1 or knockdown of MKP-1 by LVshMKP-1. *p < 0.05 by one-way ANOVA. n= 5–6 in each group. h, i The mRNA levels of APP h and
BACE1 i as assessed by qPCR in N2AAPP cells after LVMKP-1 transfection. *p= 0.017 for APP and *p= 0.038 for BACE1 by unpaired Student’s t
test. n= 3–4 in each group. j, k The promoter activity of APP j and BACE1 k assessed by luciferase assay in cells transfected with LVMKP-1. ***p <
0.001 and **p= 0.004 by unpaired Student’s t test. n= 3–4 in each group. l, m The degradation of APP l and BACE1 m assessed by half-life
measurements in LVMKP-1-transfected N2A
APP cells treated with 100 μg/ml cycloheximide (CHX). p= 0.438 for APP and p= 0.483 for BACE1 by
two-way ANOVA. n= 4–5 in each group.
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0.001), whereas AAVshMKP-1 treatment did not affect LTP in AD
mice (Fig. 6g–i). In addition, we measured the effect of MKP-1 on
synaptic structure changes in the AD mouse model. The total
number of synapses was dramatically decreased in AD mice
(10.94 ± 0.22 vs. 21.05 ± 1.57 in the control, p < 0.001; Fig. 6j, k).
However, upregulation of MKP-1 expression by AAVMKP-1
significantly increased the total number of synapses to 18.85 ±
0.25, whereas knockdown of MKP-1 expression by AAVshMKP-1
further reduced the total number of synapses to 9.00 ± 2.36 in AD
mice (p < 0.001; Fig. 6j, k). Furthermore, similar results were
observed with the thickness of postsynaptic density (PSD). The
thickness of PSD was 9.78 ± 0.63 nm in AD mice compared with
Fig. 4 MKP-1 inhibited APP processing through inactivation of the ERK/MAPK signaling pathway. a–e Immunoblot of the expression of MKP-1
b, P-ERK c, P-JNK d and P-P38 e in lysates of N2AAPP cells after overexpression of MKP-1 by LVMKP-1 or knockdown of MKP-1 by LVshMKP-1. *p <
0.05 and ***p < 0.001 by one-way ANOVA. n= 4–5 in each group. f–j Immunoblot of the expression of APP g, C89 h, C99 i and BACE1 j in
lysates of N2AAPP cells treated with the ERK inhibitor U0126, the JNK inhibitor SP600125, the P38 inhibitor SB203580 or the three inhibitors
together (Combined). *p < 0.05, **p < 0.01 and ***p < 0.001 by one-way ANOVA. n= 5–7 in each group. k, l The mRNA levels of human APP k
and BACE1 l assessed by qPCR in N2AAPP cells and N2AAPP cells treated with U0126. ***p < 0.001 for APP and *p= 0.032 for BACE1 by unpaired
Student’s t test. n= 3–4 in each group. m, n The promoter activity of APP m and BACE1 n assessed by luciferase assay in N2AAPP cells and
N2AAPP cells treated with U0126. *p= 0.036 for APP and *p= 0.040 for BACE1 by unpaired Student’s t test. n= 3–4 in each group. o, p The
degradation of APP o and BACE1 p as assessed by half-life measurements in the N2AAPP cells after U0126 treatment. p= 0.264 for APP and p=
0.847 for BACE1 by two-way ANOVA. n= 4–5 in each group.
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19.94 ± 1.34 nm in nontransgenic mice (p= 0.045). Upregulation
of MKP-1 by AAVMKP-1 restored the thickness to 21.96 ± 4.01 nm
(p= 0.018), whereas knockdown of MKP-1 by AAVshMKP-1 had no
effect on thickness at 10.05 ± 0.95 nm in the hippocampal CA1
region of AD mice (Fig. 6j, l). Notably, no obvious difference was
observed in the width of the synaptic cleft in mice treated with
AAVMKP-1 or AAVshMKP-1 (Fig. 6j, m). Together, these findings
suggest that upregulation of MKP-1 rescues synaptic deficits and
ameliorates cognitive impairments in the AD model in vivo.
DISCUSSION
MKP-1 has essential roles in regulating neuronal growth and
synaptogenesis by inhibiting MAPK signaling in the central
nervous system. Here, we reported that MKP-1 expression was
significantly reduced in the brains of patients with AD and in a
mouse model of AD. We also found that MKP-1 transcriptional
activation was regulated by Sp1. Aβ treatment decreased MKP-1
expression by upregulating Sp1. We demonstrated that MKP-1
regulated ERK/MAPK-mediated APP and BACE1 transcriptions,
thus affecting APP processing and Aβ production. These findings
reveal that inhibiting the MKP-1 signaling pathway could facilitate
AD pathogenesis. Our results further suggested that MKP-1
upregulation reduced Aβ production and plaque formation,
rescued synaptic abnormalities, and improved cognitive decline
in AD mice (Supplementary Fig. 4). Our study clearly demonstrates
the effect of MKP-1 on AD pathogenesis and its therapeutic
potential for AD treatment.
MAPKs are involved in Aβ deposition,21,38–40 tau protein
phosphorylation,21 and inflammatory responses.41 MKP-1, an
inhibitor of MAPKs,28–30 may play an essential role in AD. The
present study found that MKP-1 expression was obviously
decreased in patients with AD and AD mice. We found that a
reduction in MKP-1 resulted in the overactivation of the ERK/MAPK
Fig. 5 MKP-1 reduced Aβ generation and senile plaque numbers in APP/PS1 mice. a–c Immunoblot of the expression of MKP-1 b and P-ERK c
in the hippocampal homogenates of wild-type (WT) and APP/PS1 transgenic AD mice after overexpression of MKP-1 by AAVMKP-1 or
knockdown of MKP-1 by AAVshMKP-1. *p < 0.05, **p < 0.01 and ***p < 0.001 by one-way ANOVA. n= 4–5 in each group. d, e The number of
senile plaques detected by immunohistochemistry in the hippocampus of AD model mice after overexpression of MKP-1 by AAVMKP-1 or
knockdown of MKP-1 by AAVshMKP-1. *p < 0.05 and ***p < 0.001 by one-way ANOVA. n= 29 to 54 in each group. f, g Generation of Aβ40 f and
Aβ42 g as measured by ELISA in the hippocampal homogenates of WT and AD model mice after overexpression of MKP-1 by AAVMKP-1 or
knockdown of MKP-1 by AAVshMKP-1. *p < 0.05, **p < 0.01, and ***p < 0.001 by one-way ANOVA. n= 5 in each group. h–l Immunoblot of the
expression of APP i, C89 j, C99 k and BACE1 l in the hippocampal homogenates of WT and AD mice after overexpression of MKP-1 by AAVMKP-1
or knockdown of MKP-1 by AAVshMKP-1. *p < 0.05 and **p < 0.01 by one-way ANOVA. n= 5 in each group.
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signaling pathway and thereby increased Aβ generation. Aβ is
produced from APP via sequential cleavages by β- and γ-
secretases.1 Dysregulation of BACE1 is involved in AD pathogen-
esis, and inhibition of BACE1 reduces Alzheimer’s pheno-
types.4,37,42 Our data showed that upregulation of MKP-1
inhibited APP and BACE1 expression, leading to a reduction in
the amyloidogenic processing of APP to generate Aβ. In contrast,
downregulation of MKP-1 increased Aβ generation in AD mice.
However, it is interesting that downregulation of MKP-1 did not
affect APP or BACE1 expression or the number of neuritic plaques.
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One possibility is that reduced MKP-1 in AD models is sufficient to
increase APP and BACE1 expression so that genetic knockdown of
MKP-1 cannot induce further increases in APP and BACE1.
Growing evidence has demonstrated that ERK activation is
required for synaptic plasticity and memory.19,20 Inhibition of ERK
activation by the inhibitor SL327 causes significant long-term
memory impairments.43 However, nonspecific ERK phosphoryla-
tion or overactivation may account, at least in part, for memory
impairment owing to altered signaling in diseases. Previous studies
have suggested that ERK is overactivated in AD,21–23 and
decreasing ERK activation in the prefrontal cortex can reverse
early memory decline in AD mice.24 Consistent with these findings,
we here reported that AD mice displayed dramatically higher levels
of activated ERK at 12 months of age. All members of the MAPK
family have been implicated in AD.21,38–40 In this study, we
demonstrated that MKP-1 reduction results in the overactivation of
ERK, JNK and P38. However, our data showed that only the ERK/
MAPK pathway has key roles in Aβ generation by inhibiting the
transcription of the APP and BACE1 genes. One possibility is that
JNK and P38 have little effect on BACE1-mediated APP processing,
but they are able to participate in AD development through other
molecular mechanisms. For instance, the JNK/MAPK signaling
pathway can be activated in the synapse before the onset of
cognitive impairment.15 Inhibition of JNK activity by CEP-1347
blocked the Aβ-induced neurotoxicity and downstream c-Jun and
caspase-2 and −3 activation,44 consequently preventing synaptic
shrinkage and postsynaptic protein loss.45 Aβ-induced oxidative
stress can lead to P38/MAPK activation and tau hyperphosphoryla-
tion.17 In addition, Aβ stimulates rapid P38/MAPK activation,
leading to inflammatory gene expression and proinflammatory
cytokine release in microglia.46,47 Thus, inhibition of P38 over-
activation with MW01-2-069A-SRM significantly attenuated the
Aβ-induced increase in proinflammatory cytokines and reduced
the Aβ-mediated synaptic and behavioral deficits in mice.48
In summary, we determined that upregulation of MKP-1
significantly inhibits the amyloidogenic processing of APP by
regulating the ERK/MAPK signaling pathway, reduces the senile
plaque number and ameliorates cognitive function in a mouse
model of AD model. These findings provide novel insights into the
role of MKP-1 in the pathogenesis of AD and its potential as a new
target for AD therapy.
MATERIALS AND METHODS
Animals
APP/PS1 mice were obtained from Beijing HFK Bioscience Co. and
reared in a temperature- and humidity-controlled specific-
pathogen-free room (lights on from 7:00 a.m. to 7:00 p.m.) at
Children’s Hospital of Chongqing Medical University. The geno-
type was confirmed by PCR using tail tissue DNA. All animal
experiments were conducted in accordance with the Chongqing
Science and Technology Commission guidelines and approved by
the Animal Care Committee of Chongqing Medical University.
Patient samples
Ten postmortem human brain samples, six of which were clinically
diagnosed with AD, were obtained from the Chinese Human Brain
Bank of Zhejiang University (Supplementary Table 1). These
samples were pathologically confirmed by the Chinese Human
Brain Bank. Brain tissues were homogenized in ice-cold TRIzol
(Takara, Otsu, Shiga, Japan). Chloroform was added to separate
the phases, and then an equal volume of isopropyl alcohol was
mixed with the aqueous phase. After the pellet was washed with
70% ethanol, RNA was detected by a spectrophotometer
NanoDrop 2000 (Nanodrop Technologies, Wilmington, DE, USA).
Moreover, samples were homogenized in homogeneous buffer in
a mortar and pestle and centrifuged (12,000 g, 4 °C for 15 min) to
collect the supernatants for western blotting assay. The human
study was evaluated and approved by the Ethics Committee of
Zhejiang University (number of the research project ethical
approval document: 2018-009).
Antibodies
APP and its CTFs were detected by a polyclonal antibody C20
(1:1000) that was obtained from the laboratory of professor
Weihong Song.49 Anti-MKP-1 (1:200, #sc-2857) was obtained from
Santa Cruz Biotechnology. Anti-JNK (1:1000, #9252), anti-P-JNK
(1:1000, #4668), anti-P38 (1:1000, #8690), anti-P-P38 (1:1000,
#4511), anti-ERK (1:1000, #4695), anti-P-ERK (1:1000, #4370) and
anti-BACE1 (1:1000, #5606) were purchased from CST. Anti-β-actin
(1:3000, #A5411) antibody was purchased from Sigma.
Plasmids
Genomic DNA extracted from HEK 293 cells was used to amplify
the promoter region of human MKP-1 by PCR. From −763 bp to
+342 bp of the transcription start site at +1, six fragment
promoter regions of MKP-1 were amplified by PCR, and the
luciferase reporter gene was inserted into the pGL4.10 expression
vector (MKP-1-A, -B, -C, -D, -E, and -F; Supplementary Fig. S2). To
construct different sequences of the MKP-1 promoter, the
following primers were used: −763 fKpnI: 5′-CCGGGTACCAAAAGT
CTGGGAAACAGGAAAG, −229 fKpnI: 5′-CCGGGTACCGCTCCGAGGC
TGATGACGT, −47 fKpnI: 5′-CCGGGTACCGCTGCGAAGGACATTTGG,
+222 rHindIII: 5′-TACAAGCTTCAGGGTGCCCACTTCCAT, +342 rHin-
dIII: 5′-TACAAGCTTGAAGCGCACGTTGACAGAG, and −47 rHindIII:
5′-TACAAGCTTGAGCCTGGCCCGGGGAGCGCGTTTA.
The following series of substitution mutations of the Sp1-
binding sites in MKP-1 were constructed: for Sp1-binding site 1
in MKP-1 (Sp1-1), TCTCCGCCCCAACTCG was mutated to AAA
AAAAAAAAAAAAA; for Sp1-binding site 2 in MKP-1 (Sp1-2),
CCCCCACCCCA was mutated to AAAAAAAAAAA; for Sp1-
binding site 3 in MKP-1 (Sp1-3), AGCCCTCCTCCTCCCCG was
mutated to AAAAAAAAAAAAAAAAA; for Sp1-binding site 4 in
MKP-1 (Sp1-4), CCCCCCCTCCCCC was mutated to AAAAAAAAA
AAAA; and for Sp1-binding site 5 in MKP-1 (Sp1-5), GGCCCGC
CCCGTCCCCC was mutated to AAAAAAAAAAAAAAAAA (Sup-
plementary Table 2).
Fig. 6 MKP-1 alleviated synaptic and memory deficits in APP/PS1 mice. a–c Spatial learning and memory assessed by the Morris water maze
test in wild-type (WT) and APP/PS1 transgenic AD mice at the age of 9 months after overexpression of MKP-1 by AAVMKP-1 or knockdown of
MKP-1 by AAVshMKP-1. The escape latency to the hidden platform a during the spatial learning period. **p < 0.01 by two-way ANOVA. The
number of entries into the platform zone b and the time spent in the hidden platform-located quadrant c during the probe test in absence of
the hidden platform in mice. *p < 0.05 and **p < 0.01 by one-way ANOVA. n= 7–12 in each group. d–f Spatial learning and memory as
assessed by the Morris water maze test in WT and AD mice at the age of 12 months after overexpression of MKP-1 by AAVMKP-1 or knockdown
of MKP-1 by AAVshMKP-1. The escape latency to the hidden platform d during the spatial learning period. ***p < 0.001 by two-way ANOVA. The
number of entries into the platform zone e and the time spent in the hidden platform-located quadrant f during the probe test in absence of
the hidden platform in mice. *p < 0.05 and ***p < 0.001 by one-way ANOVA. n= 10 in each group. g–i Hippocampal CA1 LTP recorded from
brain slices of WT and AD mode mice at the age of 12 months after overexpression of MKP-1 by AAVMKP-1 or knockdown of MKP-1 by
AAVshMKP-1. **p < 0.01 by one-way ANOVA. n= 4 to 10 slices from three mice in each group. j–m Transmission electron microscopic analysis
was performed to examine the changes in synapse numbers k, PSD thickness l and spine width m in the hippocampus of WT and AD mice at
the age of 12 months after overexpression of MKP-1 by AAVMKP-1 or knockdown of MKP-1 by AAVshMKP-1. *p < 0.05 and ***p < 0.001 by one-way
ANOVA. n= 4 in each group.
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Cell culture and transfection
N2A cells were cultured in 47% Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco, New York, USA) and 47% Opti-MEM
(Gibco, New York, USA), supplemented with 1% streptomycin and
5% fetal bovine serum (FBS). N2AAPP cells stably transfected with
the human Swedish mutant APP695 were obtained from Professor
Chunjiu Zhong (Fudan University, Shanghai, China) and cultured
in complete DMEM containing G418 at a concentration of 100 µg/
ml. Cells were maintained at 37 °C in a 5% CO2 atmosphere. The
cells were seeded in six-well plates until grown to 30–40%
confluence and then transfected with LVMKP-1 or LVshMKP-1 to
produce a final MOI of 20. Approximately 8–12 h later, complete
medium was added, and cells were harvested for western blotting
72 h after that. To overexpress or knockdown MKP-1 in vitro,
lentivirus overexpressing MKP-1 (LVMKP-1) or MKP-1 carrying small
hairpin RNA (LVshMKP-1) was constructed by OBiO Technology
(Shanghai, China). siRNA against mouse MKP-1 was obtained from
Santa Cruz Biotechnology, and the MKP-1 overexpression plasmid
was synthetized by OBiO. The neuron-specific promoter P2A was
used to drive MKP-1 expression, and the H1 promoter was used
for shRNA-MKP-1.
Adeno-associated virus and microinjection
To overexpress or knockdown MKP-1 in vivo, adeno-associated
virus expressing MKP-1 (AAVMKP-1) or MKP-1 small hairpin RNA
(AAVshMKP-1) was constructed by OBiO Technology. Titers were 3 ×
1012 TU/ml. After anesthetization with sodium pentobarbital, mice
were mounted on a stereotaxic instrument, and 1 μl of AAVMKP-1 or
AAVshMKP-1 was microinjected into the lateral ventricle per
hemisphere by a drilled hole (0.4 mm posterior, ±1 mm lateral
and 3mm ventral relative to bregma). All mice received two AAV
microinjections before the behavioral test. Some mice received
AAV microinjections at the age of 6 and 9 months, and the
behavioral tests were performed at the age of 12 months. Other
mice received AAV microinjections at the age of 3 and 6 months,
and the behavioral tests were performed at the age of 9 months.
Immunohistochemistry staining
After animals were killed with an overdose of urethane, one half of
the mouse brain was immediately frozen for protein or RNA
extraction. The other half of the brain was postfixed in freshly
prepared 4% paraformaldehyde in phosphate-buffered saline
(PBS, 0.1 M, pH 7.4) for 24 h, then dehydrated with 30% sucrose
until the tissue sank to the bottom and serially sectioned into
30 μm-thick coronal sections. To eliminate residual peroxidase
activity, the slices were incubated with 3% H2O2 for half an hour.
Then, the slices were blocked with 10% bovine serum albumin
and incubated with mouse monoclonal 4G8 antibody overnight at
4 °C. Plaques were detected by the ABC and DAB methods and
counted by microscopy at × 40 magnification as described
previously.50
Quantitative real-time PCR
Total RNA was extracted from brain tissue or cells using TRIzol
reagent (Takara, Otsu, Shiga, Japan), and the concentration and
purity were detected with a spectrophotometer NanoDrop 2000
(Nanodrop Technologies, Wilmington, DE, USA). One microgram of
RNA was used to synthesize the first-strand complementary DNA
(cDNA) with the Prime Script RT reagent Kit (Takara, Otsu, Shiga,
Japan). The cDNA of MKP-1, APP and BACE1 were analyzed by
quantitative real-time PCR by using SYBR Premix Ex Taq II (Takara,
Otsu, Shiga, Japan) with the CFX Manager software detection
system (Bio-Rad). Primer sequences were as follows: MKP-1
(forward: 5′-GTACATAAGTCCATCTGAC, reverse: 5′-GGTTCTTCTA
GGAGTAGACA); APP (forward: 5′-ATGCCGTTGACAAGTATCTCG,
reverse: 5′-TCTGCCTCTTCCCATTCTCTC); BACE1 (forward: 5′-TA
CCAACCAGTCCTTCCGC, reverse: 5′-CTCCCATAACAGTGCCCGT);
and GAPDH (forward: 5′-AACTGCTTAGCACCCCTGGC, reverse: 5′-
ATGACCTTGCCCACAGCCTT). The relative expression levels of MKP-
1, APP and BACE1 cDNAs were normalized to GAPDH levels.
Western blot assay
The hippocampus and temporal cortex were lysed in homo-
geneous buffer in a mortar and pestle. The homogenates were
centrifuged (4 °C, 10,000 rpm, 15 min) to collect the supernatants.
Protein samples (30 μg) were boiled in 4 × loading buffer at 95 °C
for 10 min. The samples were then separated on 10% tris-glycine
SDS-PAGE or 16% tris-tricine SDS-PAGE and transferred onto an
immobilon-PTM polyvinylidene fluoride membrane. To block
nonspecific binding, the membranes were incubated with 5%
nonfat milk in Tris-buffered saline containing 0.1% Tween-20 at
37 °C for 1 h. The target proteins were immunoblotted with
primary antibody overnight at 4 °C. After incubation with goat
anti-rabbit IgG (1:3000; Abcam) at room temperature for 1 h, the
protein was detected with the Bio-Rad Imager using ECL Western
blotting substrate (Pierce, Waltham, USA).
Aβ ELISA
Mouse hippocampal homogenates or cell culture media were
collected. To prevent Aβ degradation, lysis buffer was added with
a protease inhibitor (Roche, Basel, Switzerland). The level of Aβ40/
Aβ42 was determined using an Aβ40/Aβ42 ELISA Kit (R&D). Samples
were measured by a microplate reader (Bio Tek Synergy H1,
Winooski, USA) at 450 nm.
Morris water maze
The Morris water maze test was introduced to detect
hippocampal-based spatial memory in mice at the ages of 9 and
12 months, as described previously.50,51 The maze consists of a
150-cm diameter circular stainless-steel pool filled with nontoxic
white paint, and the temperature was maintained at 24 ± 1 °C.
Each mouse performed a 120-s free swim to adapt to the maze
24 h before spatial learning. Then, the mice were trained to search
the hidden platform (13 cm in diameter) for four trials per day for
5 consecutive days. Upon failure to reach the hidden platform in
120 s, mice would be guided to the platform where they stayed for
20 s. A retrieval test was conducted 24 h after the last learning
trial. The Any-maze tracking system (Stoelting Co., Wood Dale,
USA) was used to record escape latency.
Electrophysiology in vitro
Mice (12 months old) were killed, and hippocampal slices (400-μm
thick) were cut coronally with a vibratome (VT1200S, Leica,
Wetzlar, Germany) at 95% O2 and 5% CO2 and then transferred
into a submersion-type incubation chamber for a 2-h recovery at
35 °C.52 Field excitatory postsynaptic potentials were recorded
from hippocampal CA1 stratum radiatum by stimulation of the
Schaffer collateral-commissural pathway. Theta burst stimulation
was delivered to induce LTP after obtaining a stable baseline. Data
acquisition was performed with the PatchMaster v2.73 software
(HEKA Electronic, Lambrecht/Pfalz, Germany).
Transmission electron microscopy
Transmission electron microscopy (TEM) was used to detect the
ultrastructures and neurons, as described previously.53 Mice were
overdosed with urethane and then transcardially perfused with
2.5% glutaraldehyde. Each mouse brain was rapidly separated on
ice, and a 1mm tissue sample was excised from the hippocampal
CA1 area. The samples were then fixed in 4% glutaraldehyde for
more than 24 h and embedded in Epon812 epoxy resin. Then, the
samples were sliced into 1-μm-thick flakes. Philips EM208S TEM
(Philips, Amsterdam, Netherlands) was used to observe the
ultrastructures and neurons after double staining with uranyl
acetate and lead citrate. The presence of at least three vesicles in
the presence of the presynaptic bouton and a PSD was used to
identify synapses. Random synaptic images obtained according to
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a previously used method53,54 were used to measure the number
of synapses and PSD synaptic cleft width and thickness. All
measures were carried out in a double-blind manner.
Luciferase assay
To determine the promoter activity, plasmids containing the
promoter regions of the human APP and BACE1 genes were
constructed.3,55 The plasmids were transfected into N2AAPP cells
using Lipofectamine 2000 (Invitrogen, Carlsbad, USA), and then
MAPK inhibitors were administered for 24 h. The Dual-Luciferase
Reporter Assay System (Promega, Madison, USA) was used to
measure the activities of firefly luciferase and Renilla luciferase
sequentially.
Aβ oligomer preparation
The Aβ42 peptide was obtained from GL Biochem Ltd. (Shanghai,
China). To enhance oligomer formation, 1 mM hexafluoroisopro-
panol was used to dissolve Aβ42, which was then evaporated to
form a dried film. The film was then dissolved in dimethyl
sulfoxide to 5mM, which was then mixed with PBS and incubated
for 48 h at 4 °C. After incubation, the preparation was centrifuged
(14,000× g, 10 min), and the supernatant was collected.
Cycloheximide treatment
For the MKP-1 degradation experiment (half-life measurements),
Aβ42 (10 μM) was used to treat N2A cells for 24 h. For the APP and
BACE1 degradation experiments, N2AAPP cells were treated with
ERK inhibitor and LVMKP-1 for 48 h. N2A and N2A
APP cells were
harvested at different time points after cycloheximide treatment
(100 μg/ml).
EMSA
EMSA was conducted as described previously.37 In brief, nuclear
extracts of HEK 293 cells were prepared by a cytoplasmic nuclear
isolation kit (Invent Biotechnologies, EdenPrairie, USA) supple-
mented with a protease inhibitor. An IRDye 700–labeled Sp1 oligo
(5′-ATTCGATCGGGGCGGGGCGAGC) was mixed with nucleoprotein
(2 μg) at room temperature for 30 min in the dark, and the gels
were scanned by using the Odyssey system (LI-COR Biosciences,
Lincoln, USA). Unlabeled wild-type and mutant (5′-GGTAACTA
CTAAGTTATTTTCAAGCTACTTAA) Sp1 were used to compete for
binding in the competition assay.
Statistical analysis
All data are expressed as the mean ± SEM. ANOVA or two-tailed
Student’s t tests were used to analyze the data as appropriate.
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